Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

Overview of attention for article published in Cardiovascular Diabetology, January 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter: 1 X user

patent: 4 patents

Citations

dimensions_citation: 209 Dimensions

Readers on

mendeley: 152 Mendeley
citeulike: 2 CiteULike

Summary X Patents Dimensions citations

So far, Altmetric has seen 4 patents that reference this research output.

CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY

Application EA-037712-B1

Eurasian Patent Organisation

USE OF LINAGLIPTIN IN CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY

Application EP-3744327-A1

European Patent Office

USE OF LINAGLIPTIN IN CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY

Application EP-3409279-A1

European Patent Office

USE OF LINAGLIPTIN IN CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY

Application WO-2014140284-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.